BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
See today's BioWorld
Home
» 'One issue to clarify' for Acacia; Barhemsys launch plans a go despite CRL
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
'One issue to clarify' for Acacia; Barhemsys launch plans a go despite CRL
Oct. 9, 2018
By
Nuala Moran
No Comments
LONDON – Acacia Pharma Group plc vowed to carry on with 2019 U.S. launch plans for its postoperative nausea and vomiting (PONV) product Barhemsys, despite receiving a complete response letter (CRL) from the FDA.
BioWorld